The Tear Film and Ocular Surface Society Dry Eye Workshop II report recommends a comprehensive, multistage management algorithm for the disease that is both evidence-based and personalized.
For patients suffering from dry eye disease (DED), new developments continue to offer hope and give physicians new and innovative ways to approach the disease.
The 2017 Tear Film and Ocular Surface Society (TFOS) Dry Eye Workshop II report (TFOS DEWS II), updated the definition of DED and expanded its scope.1
The cycle of tear film instability and hyperosmolarity creates ocular surface inflammation, damage, and neurosensory abnormalities1 that can frustrate both patients and clinicians. The report recommends a comprehensive, multistage management algorithm for DED that is both evidence-based and personalized, depending on the severity of the disease.
The goal of DED treatment is to restore the homeostasis of the ocular surface and tear film.
The TFOS DEWS II now defines DED as a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles.
The TFOS DEWS II recognizes that management algorithms are more complicated in DED than in other diseases, because DED can vary greatly from one patient to another.
1. Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II Report Executive Summary. Ocul Surf. 2017;15(4):802-12.
2. Hill J, Bird H, Johnson S. Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial. Ann Rheum Dis. 2001;60(9):869-75.
3. Blackie CA, Coleman CA, Holland EJ. The sustained effect (12 months) of a single-dose vectored thermal pulsation procedure for meibomian gland dysfunction and evaporative dry eye. Clin Ophthalmol. 2016;10:1385-96.
4. Toyos R, McGill W, Briscoe D. Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction; a 3-year retrospective study. Photomed Laser Surg 2015;33(1):41-6.
5. Ogawa M, Dogru M, Toriyama N, et al. Evaluation of the Effect of Moist Chamber Spectacles in Patients With Dry Eye Exposed to Adverse Environment Conditions. Eye Contact Lens 2018;44(6):379-83.
6. Jirsova K, Brejchova K, Krabcova I, et al. The application of autologous serum eye drops in severe dry eye patients; subjective and objective parameters before and after treatment. Curr Eye Res. 2014;39(1):21-30.
7. Bavinger JC, DeLoss K, Mian SI. Scleral lens use in dry eye syndrome. Curr Opin Ophthalmol. 2015;26(4):319-24.